nuclear cap binding subunit 3Genealiases: C17orf85 · ELG · HSA277841
Q-omics provides the consensus-scored NCBP3 profile across patient tissues and cancer cell-line models. NCBP3 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NCBP3 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, NCBP3 protein abundance shows 26,177 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, HNSC, and GBM as cancer lineages where NCBP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NCBP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NCBP3 survival associations across molecular data types. NCBP3 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NCBP3 RNA expression–survival associations across cancer types. High NCBP3 expression shows unfavorable associations in ACC, LGG, LUSC and KICH, but favorable associations in SCLC and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for NCBP3 RNA expression.
This table summarizes NCBP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for NCBP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NCBP3 shows lower tumor expression in KICH, BRCA and THCA and higher tumor expression in HNSC, LIHC and CHOL. The HNSC box plot shows higher NCBP3 RNA expression in tumor versus normal tissue (log2 FC = +0.649, t-test p < 0.001).
This table shows molecular features associated with NCBP3 in patient tissues and cancer cell lines. In patient samples, NCBP3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NCBP3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE.
